Sugi Predict

Sugi Predict / Compounds / SCHEMBL700588

SCHEMBL700588

SCHEMBL700588

O=C(O)c1cc2cc(Br)ccc2s1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.66
▸ BCL2L1 Q07817 1/20 0.59
▸ MEN1 O00255 1/20 0.59
▸ RAB9A P51151 1/20 0.59
▸ KMT2A Q03164 1/20 0.59
▸ GPR35 Q9HC97 2/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ PTPN2 P17706 2/20 0.48
▸ CLK1 P49759 4/20 0.46
▸ DYRK1A Q13627 3/20 0.46
▸ DYRK1B Q9Y463 3/20 0.46
▸ HSP90AA1 P07900 1/20 0.46
▸ TBXAS1 P24557 1/20 0.46
▸ HDAC1 Q13547 4/20 0.45
▸ HDAC3 O15379 1/20 0.43
▸ HDAC4 P56524 1/20 0.43
▸ HDAC7 Q8WUI4 1/20 0.43
▸ HDAC2 Q92769 1/20 0.43
▸ HDAC10 Q969S8 1/20 0.43
▸ HDAC11 Q96DB2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29481855 1.00 LMNA (0.66) LMNABCL2L1MEN1RAB9AKMT2A
SCHEMBL30151656 0.85 BCL2L1 (0.59) LMNABCL2L1MEN1RAB9AKMT2A
SCHEMBL498133 0.85 BCL2L1 (0.59) LMNABCL2L1MEN1RAB9AKMT2A
SCHEMBL30193075 0.84 LMNA (0.64) LMNABCL2L1MEN1RAB9AKMT2A
SCHEMBL21406460 0.84 LMNA (0.64) LMNABCL2L1MEN1RAB9AKMT2A
SCHEMBL30980400 0.84 LMNA (0.64) LMNAMEN1RAB9AKMT2AL3MBTL1
SCHEMBL19964501 0.84 LMNA (0.64) LMNAMEN1RAB9AKMT2AL3MBTL1
SCHEMBL121775 0.84 LMNA (0.69) LMNABCL2L1MEN1RAB9AKMT2A
SCHEMBL30474831 0.83 LMNA (0.63) LMNAMEN1RAB9AKMT2AL3MBTL1
SCHEMBL256555 0.83 LMNA (0.63) LMNAMEN1RAB9AKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2167077-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR Bayer Schering Pharma Aktiengesellschaft (DE) 2010-03-31 — — EP claimed
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AG (DE) 2009-01-22 — — US claimed
WO-2008152099-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-18 — — WO claimed
US-12570679-B2 STAT3 protein degraders REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2026-03-10 — — US disclosed
US-20260042788-A1 STAT6 COMPOUNDS GILEAD SCIENCES INC (US) 2026-02-12 — — US disclosed
EP-4680247-A1 DPP1 INHIBITORS WITH POLYCYCLIC LINKERS AND USES THEREOF Insmed Incorporated (US) 2026-01-21 — — EP disclosed
US-12522623-B2 Small molecule STAT protein degraders REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2026-01-13 — — US disclosed
US-12441724-B2 Inhibitors of plasma kallikrein and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-10-14 — — US disclosed
US-12378224-B2 Heteroaryl compounds and their use as Mer inhibitors DONG-A SOCIO HOLDINGS CO., LTD. (KR) 2025-08-05 — — US disclosed
US-20250179055-A1 Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof INNOVSTONE THERAPEUTICS LIMITED (CN) 2025-06-05 — — US disclosed
CN-120058834-A Aryl phosphoric acid STAT3 degradation agent, composition and application 杭州和正医药有限公司 2025-05-30 — — CN disclosed
US-6201006-B1 ANTICOAGULANTS C & C RESEARCH LABORATORIES (KR) 2001-03-13 — — US disclosed
US-5962695-A ANTICOAGULANT DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1999-10-05 — — US disclosed
EP-0918768-A1 AROMATIC AMIDINE DERIVATIVES USEFUL AS SELECTIVE THROMBIN INHIBITORS C & C Research Laboratories (KR) 1999-06-02 — — EP disclosed
US-5866577-A AN ANTICOAGULANT AGENT DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1999-02-02 — — US disclosed
WO-1997045424-A1 AROMATIC AMIDINE DERIVATIVES USEFUL AS SELECTIVE THROMBIN INHIBITORS C & C RESEARCH LABORATORIES (KR) 1997-12-04 — — WO disclosed
US-5620991-A ANTICOAGULANTS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1997-04-15 — — US disclosed
US-5576343-A ANTICOAGULANTS; BLOOD-COAGULATION FACTOR X INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1996-11-19 — — US disclosed
EP-0540051-B1 Aromatic amidine derivatives and salts thereof DAIICHI SEIYAKU CO (JP) 1996-04-03 — — EP disclosed
EP-0540051-A1 Aromatic amidine derivatives and salts thereof DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1993-05-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042788-A1 STAT6 COMPOUNDS STAT6, IL6ST, NFATC1 LMNA 2995/4885BCL2L1 492/4885MEN1 4198/4885
US-12378224-B2 Heteroaryl compounds and their use as Mer inhibitors MERTK, RET, ERBB2 LMNA 1144/4885BCL2L1 3425/4885MEN1 379/4885
US-12441724-B2 Inhibitors of plasma kallikrein and uses thereof KLKB1, KLK1, KLK5 LMNA 1722/4885BCL2L1 4794/4885MEN1 686/4885
US-12570679-B2 STAT3 protein degraders STAT3, JAK2, IL6ST LMNA 3578/4885BCL2L1 793/4885MEN1 4262/4885
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 LMNA 2836/4885BCL2L1 3789/4885MEN1 4355/4885
US-20250179055-A1 Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof PCSK9, LPL, LYPLA1 LMNA 81/4885BCL2L1 3456/4885MEN1 2743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.